-
CHMP recommends the treatment of HER2-positive metastasis breast cancer with curtojudan single anti-Deruxtecan
Time of Update: 2020-12-23
Daiichi Sankyo and AstraZeneca's curvature bead mono-deuxtecan have been recommended by the European Union for the treatment of non-removable or metastasis HER2-positive breast cancer patients who have received two or more therapies.
-
Good and comfortable
Time of Update: 2020-12-23
Network Source: Network Copyright Notice: All text, images and audio and video materials that indicate "Source: Mets Medicine" or "Source: MedSci Originals" are owned by Metz Medicine and are not authorized to be reproduced by any media, website or individual, and are authorized to be reproduced with the words "Source: Mets Medicine".
-
Br J Cancer: Systematic assessment and meta-analysis reveal the role of immersive T-cell markers in the development of cervical cancer
Time of Update: 2020-12-23
The results show that successful immune escape can reduce HPV infection and T-cell immersion in precancer endocrine cells, while infusion cancer is highly immunogenic, and as cervical disease develops, the immersion of regulated T-cells increases.
-
Eur Heart J: Risk of heart disease in patients treated with immunosuppressants
Time of Update: 2020-12-23
researchers included 25,573 lung cancer patients, 743 of whom were treated with programmed cell death 1 inhibitor (PD1i), with an absolute risk of 9.7% of one-year heart events .95% confidence interval (CI) of 6.8-12.5.
-
JCO:BLOOM Study - Osimertinib's application in EGFRm and LM non-small cell lung cancer patients
Time of Update: 2020-12-23
recently, a BLOOM study conducted at the National Taiwan University Hospital assessed the efficacy and safety of osimertinib in patients with advanced LMs in EGFRm, who were still progressing after treatment with EGFR-TKI.
-
ABO different blood types, different risk of disease, see what disease you are prone to! With blood type control table
Time of Update: 2020-12-23
studies have shown that people with type A blood are more likely to develop cardiovascular cancer, especially in patients with cerebral infarction, the highest blood type in the world.
-
Gynaecological Tumor Investigation Case . . After 82 years of age/BRCAwt/heart attack, Olapali maintenance therapy has a significant effect on patients with advanced relapsed ovarian cancer, PFS over 22 months!
Time of Update: 2020-12-23
The patients in this case were BRCA wild PSR ovarian cancer, and PFS had reached 22 months after maintenance treatment with Olapali, significantly exceeding the PFS (13 months) time after initial treatment, and follow-up indicators were good, adverse reactions were toned, and there were no signs of disease progression.
-
Professor Pan Shiyang, Jiangsu Provincial People's Hospital: There is a long way to go to detect circulating tumor cells
Time of Update: 2020-12-23
afternoon of the 13th, at the POCT marker conversion sub-forum, Professor Pan Shiyang, Director of the Department of Inspection of Jiangsu Provincial People's Hospital, gave a speech on the topic of "CTC separation and detection of existing technology", and the artery network made an editing of its wonderful views.
-
Mol Cancer: No biopsy, blood draw to detect, the gospel of gastric cancer patients with immunotherapy!
Time of Update: 2020-12-23
reported that circulating tumor cell DNA (ctDNA) can be used to identify genetic changes and predict prognostics, analyze drug resistance to targeted treatments, and monitor the recurrence or progression of stomach cancer.
-
Cell Death Differ: HPV mediated EGFR signal transducting pathridges promote the proliferation of cervical cancer cells
Time of Update: 2020-12-23
HPV-induced malignancies are mainly driven by viral cancer-causing genes E6 and E7, which increase cell proliferation and enhance cell survival by regulating the host cell signaling path path, which eventually results in malignant transformation of infected cells.
-
JAMA: The effect of Capedabin maintenance therapy on the efficacy of early triple negative breast cancer
Time of Update: 2020-12-23
the study's main endpoint was a five-year disease-free survival rate, which was the time between random grouping and the first occurrence of the following events: local recurrence, distant metastasis, lateral breast cancer, or death from any cause.
-
Breakthrough! Breast Cancer Vaccine GP2's latest study finds no recurrence in 5 years after HER2-positive breast cancer surgery!
Time of Update: 2020-12-23
: In this 4-arm, forward-looking, randomized, single-blind, multi-center Phase II clinical trial, patients with non-positive lymph nodes and high-risk lymph node-negative breast cancer received standard treatment.
CSF secreted whole-cell vaccine combination, compared with the vaccine-free group, and another trial was Her-2 negative advanced breast cancer, using Hercetin, cyclophosphamide, GM.
-
TC-210 Treatment of refracilable mesotheliosis-positive solid tumors: Phase I/II clinical trials yielded positive results
Time of Update: 2020-12-23
Dr Garry Menzel, President and CEO of TCR2 Therapeutics, said: "While the focus of any Phase I clinical trial is safety, the tumor retreat we observed using gawocabtagene autoleucel as a single drug supports our belief in TRuC-T cells.
-
J clin oncol: Results of clinical trials of DARPin drug MP0250 for the first time using solid tumors
Time of Update: 2020-12-23
STRUCTURE MP0250 is a DARPin candidate drug that specificly inhibits endotrine growth factors (VEGF) and hepatocellular growth factors (HGF) to damage the tumor micro-environment.
-
New advances in myeloma treatment, the new mechanism of action drug Selinexor (ATG-010) three treatment options were selected in the latest edition of NCCN® multiple myeloma diagnosis and treatment guidelines
Time of Update: 2020-12-23
On December 15th Deki Pharmaceuticals Co., Ltd. ("Deki Pharmaceuticals") announced that the National Comprehensive Cancer Network (NCCN? In the latest edition of the Clinical Practice Guide for Multip
-
Red meat is listed by WHO as a carcinogen, experts: not talking about "safe dose" is a hooligan
Time of Update: 2020-12-23
In the cold winter, the most happy is to eat a hot pot. Fat cow, fat sheep, pork balls, all kinds of meat, there is always a way to satisfy your taste buds, and then drink a bowl of steaming broth, c
-
Br J Cancer: miR-199b-5p-DDR1-ERK signaling pathline mediates emT processes to inhibit the metastasis of prostate cancer
Time of Update: 2020-12-23
in PCa, DDR1 is a target mechanism study of miR-199b-5p, which shows that miR-199b-5p inhibits the expression of the gene by directly targeting the 3'-UTR region of DDR1, ultimately suppressing the superskin-interstate transformation (EMT)-related esoteric esoteric transformation (EMT) induced by the DDR1 activation ERK signal path.
-
Doctors compete to cure lung cancer, this high incidence no one asks! The patient suffered from physical and mental pain for a long time
Time of Update: 2020-12-23
" patients are generally very eager for treatment, but do not know where to look, the disease has been repeatedly delayed; " Wang Wenlin told 39 health, even if some hospitals have diagnosis and treatment of chest wall diseases, such operations are done by pediatrics, some orthopaedics, some thoracic surgery, irregular diagnosis and treatment, resulting in unsatisfactory treatment results, urgent need for social attention, urgent need for thoracic surgeons to pay attention to.
-
J Thromb Haemost: Clinical history of cancer-related visceral venous thrombosis
Time of Update: 2020-12-23
recently, a study published in Journal of Thrombosis and Haemostasis, an authoritative journal of thrombosis and clotting diseases, aims to compare the characteristics and outcomes of cancer-related SVT and conventional site VTE patients.
12-month follow-up, the researchers assessed relapsed VTE, haemorrhage, and all-cause mortality.
-
Br J Cancer: An alternative strategy for reversing drug resistance to multiple myeloma
Time of Update: 2020-12-23
, the study suggests another mechanism for the development of non-mutant PI resistance, which also explains why PI recurrence is inevitable and why patients regain sensitivity after "dosing day." the study also proposed a strategy for the elimination of drug-resistant cells by the observational genetics.
